☰

Shelley J. Force Aldred, Ph.D. - Publications

Affiliations: 
Stanford University, Palo Alto, CA 
Tree Info Grants Similar researchers PubMed Report error

13 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Trinklein ND, Pham D, Schellenberger U, Buelow B, Boudreau A, Choudhry P, Clarke SC, Dang K, Harris KE, Iyer S, Jorgensen B, Pratap PP, Rangaswamy US, Ugamraj HS, Vafa O, ... ... Force Aldred S, et al. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies. Mabs. PMID 30698484 DOI: 10.1080/19420862.2019.1574521  0.773
2019 Clarke S, Dang K, Li Y, Sankaran P, Pham D, Balasubramani A, Davison L, Harris K, Jorgensen B, Schellenberger U, Trinklein N, Ugamraj H, Buelow R, Van Schooten W, Force Aldred S, et al. A novel CD3xPSMA bispecific antibody for efficient T cell mediated killing of prostate tumor cells with minimal cytokine release. Journal of Clinical Oncology. 37: 324-324. DOI: 10.1200/Jco.2019.37.7_Suppl.324  0.768
2019 Buelow B, Clarke S, Dang K, Li J, Rancan C, Li Y, Sankaran P, Pham D, Balasubramani A, Davison L, Harris K, Jorgensen B, Schellenberger U, Trinklein N, Ugamraj H, ... ... Force Aldred S, et al. Evaluation of monovalent versus biparatopic CD3xPSMA bispecific antibodies for t-cell mediated killing of prostate tumor cells with minimal cytokine release. Journal of Clinical Oncology. 37: e16519-e16519. DOI: 10.1200/Jco.2019.37.15_Suppl.E16519  0.77
2019 Malik H, Buelow B, Rangaswamy U, Balasubramani A, Boudreau A, Dang K, Davison L, Force Aldred S, Harris KM, Iyer S, Jorgensen B, Pham D, Prabhakar K, Schellenberger U, Ugamraj H, et al. TNB-486, a Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills CD19-Positive Tumor Cells with Minimal Cytokine Secretion Blood. 134: 4070-4070. DOI: 10.1182/Blood-2019-123226  0.768
2018 Clarke SC, Ma B, Trinklein ND, Schellenberger U, Osborn MJ, Ouisse LH, Boudreau A, Davison LM, Harris KE, Ugamraj HS, Balasubramani A, Dang KH, Jorgensen B, Ogana HAN, Pham DT, ... ... Force Aldred S, et al. Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies. Frontiers in Immunology. 9: 3037. PMID 30666250 DOI: 10.3389/fimmu.2018.03037  0.658
2018 Buelow B, Choudhry P, Clarke S, Dang K, Davison L, Force Aldred S, Harris K, Pham D, Pratap P, Rangaswamy U, Schellenberger U, Shah N, Trinklein N, Ugamraj H, Wiita A, et al. Development of a fully human t-cell engaging bispecific antibody for the treatment of multiple myeloma. Journal of Clinical Oncology. 36: 60-60. DOI: 10.1200/Jco.2018.36.5_Suppl.60  0.761
2018 Force Aldred S, Boudreau A, Buelow B, Clarke S, Dang K, Davison L, Harris K, Iyer S, Jorgensen B, Ogana H, Pham D, Pratap P, Rangaswamy U, Schellenberger U, Trinklein N, et al. Multispecific antibodies targeting CD38 show potent tumor-specific cytotoxicity. Journal of Clinical Oncology. 36: 57-57. DOI: 10.1200/Jco.2018.36.5_Suppl.57  0.724
2018 Rangaswamy U, Boudreau A, Buelow B, Clarke S, Dang K, Davison L, Force Aldred S, Harris K, Iyer S, Jorgensen B, Ogana H, Pham D, Pratap P, Trinklein N, Schellenberger U, et al. A novel T-cell bispecific antibody platform for efficient T-cell mediated killing of tumor cells with minimal cytokine release. Journal of Clinical Oncology. 36: 209-209. DOI: 10.1200/Jco.2018.36.5_Suppl.209  0.773
2018 Buelow B, Choudry P, Clarke S, Dang K, Davison L, Force Aldred S, Harris K, Pratap P, Pham D, Rangaswamy U, Schellenberger U, Shah N, Trinklein N, Ugamraj H, Wiita A, et al. Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma. Journal of Clinical Oncology. 36: 8034-8034. DOI: 10.1200/Jco.2018.36.15_Suppl.8034  0.728
2018 Malik H, Buelow B, Avanzino B, Balasubramani A, Boudreau A, Clarke S, Dang K, Davison L, Force Aldred S, Harris K, Jorgensen B, Li Y, Medlari H, Narayan K, Ogana H, et al. A Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills Lymphoma Cells with Minimal Cytokine Secretion Blood. 132: 1671-1671. DOI: 10.1182/Blood-2018-99-118913  0.768
2018 Foureau DM, Bhutani M, Robinson M, Guo F, Pham D, Force Aldred S, Buelow B, Rigby K, Tjaden E, Leonidas M, Atrash S, Ndiaye AP, Symanowski J, Voorhees PM, Usmani SZ. Ex Vivo Assessment of Tnb-383B, a Bcma-Bispecific Antibody, Against Primary Tumor and Endogenous T Cells from Relapsing Multiple Myeloma Patients Blood. 132: 1940-1940. DOI: 10.1182/blood-2018-99-118881  0.442
2014 Smith RP, Eckalbar WL, Morrissey KM, Luizon MR, Hoffmann TJ, Sun X, Jones SL, Force Aldred S, Ramamoorthy A, Desta Z, Liu Y, Skaar TC, Trinklein ND, Giacomini KM, Ahituv N. Genome-wide discovery of drug-dependent human liver regulatory elements. Plos Genetics. 10: e1004648. PMID 25275310 DOI: 10.1371/Journal.Pgen.1004648  0.622
2007 Trinklein ND, Karaöz U, Wu J, Halees A, Force Aldred S, Collins PJ, Zheng D, Zhang ZD, Gerstein MB, Snyder M, Myers RM, Weng Z. Integrated analysis of experimental data sets reveals many novel promoters in 1% of the human genome. Genome Research. 17: 720-31. PMID 17567992 DOI: 10.1101/Gr.5716607  0.639
Show low-probability matches.